Abstract
Rare diseases (RDs) are those that affect a small fraction of the total population. In India, where resources are scarce, the healthcare infrastructure and policy framework are focused on mitigating diseases that affect a large number of people. As a result, many cases of RDs remain unreported, undiagnosed, and untreated. To understand the current level of RD awareness among healthcare professionals (HCPs) and researchers, as they are key stakeholders in diagnosis, treatment, policy making, and drug development, we conducted a survey based on identification of an RD, time for diagnosis, treatment options, and relationship with family history and geographic location. The survey was divided into two parts, one for researchers and the other for healthcare professionals, each consisting of 22 questions. We observed that among all our respondents, 31% of researchers and 29% of HCPs did not know the time required for diagnosis of a rare disease they mentioned in the survey. They identified the importance of family history but failed to realize its association with geographic location. The results from the exploratory study can provide information for enabling larger studies to develop recommendations and policies that can improve awareness about RDs in healthcare communities.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
CDSCO 2019 New drugs and clinical trials rule (https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/NewDrugs_CTRules_2019.pdf)
Choudhury MC and Saberwal G 2019a The role of patient organizations in the rare disease ecosystem in India: an interview based study. Orphanet J. Rare Dis. 14 117
Choudhury MC and Saberwal G 2019b The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study. Orphanet J. Rare Dis. 14 241
Chung C, Chu ATW and Chung BHY 2022 Rare disease emerging as a global public health priority. Front. Public Health 10 1028545
Colah R, Italia K and Gorakshakar A 2017 Burden of thalassemia in India: The road map for control. Pediatric Hematol. Oncol. J. 2 79–84
FDA 2022 Search orphan drug designations and approvals (https://www.accessdata.fda.gov/scripts/opdlisting/oopd/)
Ferreira CR 2019 The burden of rare diseases. Am. J. Med. Genet. A 179 885–892
Frangoul H, Altshuler D, Cappellini MD, et al. 2021 CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N. Engl. J. Med. 384 252–260
Gorospe JR, Singhal BS, Kainu T, et al. 2004 Indian Agarwal megalencephalic leukodystrophy with cysts is caused by a common MLC1 mutation. Neurology 62 878–882
Kaur B 2019 India's rare diseases policy hangs in balance (https://www.downtoearth.org.in/news/health/india-s-rare-diseases-policy-hangs-in-balance-62611)
Li X, Zhang X, Zhang S, et al. 2021 Rare disease awareness and perspectives of physicians in China: a questionnaire-based study. Orphanet J. Rare Dis. 16 171
Mendell JR, Al-Zaidy S, Shell R, et al. 2017 Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 377 1713–1722
Ministry of Health & Family Welfare 2021 National Policy for Treatment of Rare Diseases (NPTRD) (https://main.mohfw.gov.in/sites/default/files/Final%20NPRD%2C%202021.pdf)
Mohanty SS, Parihar S, Hooda RK, et al. 2022 Prevalence of sickle cell anemia, β-thalassemia and glucose-6-phosphate dehydrogenase deficiency among the tribal population residing in the Aravali hills of Sirohi region of Rajasthan state. Clin. Epidemiol. Global Health 13 100916
Mondal SK and Mandal A 2016 Prevalence of thalassemia and hemoglobinopathy in eastern India: A 10-year high-performance liquid chromatography study of 119,336 cases. Asian J. Transfus. Sci. 10 105–110
Nguengang Wakap S, Lambert DM, Olry A, et al. 2020 Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur. J. Hum. Genet. 28 165–173
Ozelo MC, Mahlangu J, Pasi KJ, et al. 2022 Valoctocogene roxaparvovec gene therapy for hemophilia A. N. Engl. J. Med. 386 1013–1025
Panigrahi I and Marwaha RK 2007 Mutational spectrum of thalassemias in India. Indian J. Hum. Genet. 13 36–37
Richter T, Nestler S, Parr R, et al. 2015 Rare disease terminology and definitions - A systematic global review: Report of the ISPOR Rare Disease Special Interest Group. Value Health 18 906–914
Sanders TI 1983 The Orphan Drug Act. Prog. Clin. Biol. Res. 127 207–215
US-FDA 2022 Approved cell and gene therapy products (https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products)
Valk J 2004 Comment on: Indian Agarwal megalencephalic leukodystrophy with cysts is caused by a common MLC1 mutation. Neurology 63 2197
von Gizycki R 2010 Contribution of rare disease patient organisations to medical education. Orphanet J. Rare Dis. 5 25
Yadav L 2018 Health ministry rolls back National Policy for Treatment of Rare Diseases. PharmBiz (http://www.pharmabiz.com/NewsDetails.aspx?aid=112990&sid=1)
Author information
Authors and Affiliations
Corresponding authors
Additional information
Corresponding editor: Sudha Bhattacharya
This article is part of the Topical Collection: The Rare Genetic Disease Research Landscape in India.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Vashishta, L., Bapat, P., Bhattacharya, Y. et al. A survey of awareness of diagnosis and treatment of rare diseases among healthcare professionals and researchers in India. J Biosci 48, 37 (2023). https://doi.org/10.1007/s12038-023-00363-1
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12038-023-00363-1